… 8 and diabetes 9,10 is standard evidence-based practice, the concept of treating obesity to
reduce the risk of cardiovascular … for overweight or obesity improve cardiovascular outcomes. …

… outcome and demonstrates reduced CVD events in persons with obesity and prior CVD
but without diabetes, semaglutide 2.4 mg once weekly treatment should inform obesity …

… comorbidity and metabolic outcomes over periods ≥ 6 … , and cardiovascular outcomes of 12
months of semaglutide. … metabolic and cardiovascular outcomes achieved by semaglutide in …

… In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in …
established CVD and overweight or obesity but without diabetes. In SELECT, semaglutide was …

… diabetes medications, c-pap machines, anti-hypertensives and improve cardiovascular
outcomes. … in our study include patients not reaching the maximum dose of semaglutide (ie, 1.7 …

… We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven,
randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular …

… The primary composite outcome was the first occurrence of cardiovascular death, nonfatal
… We hypothesized that semaglutide would be noninferior to placebo for the primary outcome. …

… with diabetes. While few reviews focused on obese/overweight individuals without diabetes,
we aimed to perform a systematic review of semaglutide and liraglutide in randomized …

… administered dose of 2.4 mg semaglutide on CV outcomes compared with placebo in people
without diabetes but who were living with overweight or obesity and who suffered from a …

… Cardiovascular (CV) disease (CVD) is the leading cause of morbidity and mortality in patients
with type 2 diabetes (T2D).1 CV outcomes trials (CVOTs) have demonstrated the CV safety …